Holen Sie sich die Stockscreener-App
1.95
2.01%
-0.04
Schlusskurs vom Vortag:
$1.99
Offen:
$1.96
24-Stunden-Volumen:
28,864
Relative Volume:
0.34
Marktkapitalisierung:
$51.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.47M
KGV:
-1.5726
EPS:
-1.24
Netto-Cashflow:
$-12.19M
1W Leistung:
+28.29%
1M Leistung:
+0.00%
6M Leistung:
-20.08%
1J Leistung:
-2.50%
1-Tages-Spanne:
$1.8234
$2.04
1-Wochen-Bereich:
$1.51
$2.1942
52-Wochen-Spanne:
$1.45
$3.48
Heartbeam Inc Stock (BEAT) Company Profile
Firmenname
Heartbeam Inc
Sektor
Branche
Telefon
408-899-4443
Adresse
2118 WALSH AVE., SUITE 210, SANTA CLARA
Vergleichen Sie BEAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAT
Heartbeam Inc
|
1.95 | 51.26M | 0 | -14.47M | -12.19M | -1.24 |
|
VEEV
Veeva Systems Inc
|
225.77 | 34.18B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
56.69 | 9.62B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
53.77 | 7.09B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
84.40 | 6.94B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.64 | 6.06B | 906.14M | -52.62M | 89.62M | -0.3621 |
Heartbeam Inc Stock (BEAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-09-11 | Eingeleitet | Needham | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Neutral |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-04-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-07-26 | Bestätigt | Lake Street | Buy |
| 2018-04-26 | Bestätigt | The Benchmark Company | Buy |
| 2018-02-23 | Bestätigt | Dougherty & Company | Buy |
| 2017-11-08 | Bestätigt | Dougherty & Company | Buy |
| 2017-10-26 | Eingeleitet | Raymond James | Outperform |
| 2017-10-24 | Eingeleitet | SunTrust | Buy |
| 2017-08-09 | Bestätigt | Dougherty & Company | Buy |
| 2017-07-19 | Bestätigt | The Benchmark Company | Buy |
| 2017-04-11 | Bestätigt | Dougherty & Company | Buy |
| 2016-12-02 | Eingeleitet | Dougherty & Company | Buy |
| 2016-09-13 | Eingeleitet | Sidoti | Buy |
| 2016-08-03 | Bestätigt | The Benchmark Company | Buy |
| 2015-07-28 | Bestätigt | Dougherty & Company | Buy |
| 2013-10-24 | Eingeleitet | The Benchmark Company | Buy |
| 2013-08-21 | Eingeleitet | Dougherty & Company | Buy |
Alle ansehen
Heartbeam Inc Aktie (BEAT) Neueste Nachrichten
HeartBeam, AccurKardia Announce Strategic Collaboration - Diagnostic and Interventional Cardiology
HeartBeam names new auditor after Marcum resignation By Investing.com - Investing.com Nigeria
HeartBeam names new auditor after Marcum resignation - Investing.com
HeartBeam partners with AccurKardia to enhance cardiac care - Yahoo Finance
HeartBeam and AccurKardia partner on ECG tech By Investing.com - Investing.com South Africa
HeartBeam (NASDAQ: BEAT) And AccurKardia Partner To Advance Remote ECG Monitoring - Barchart.com
HeartBeam, AccurKardia Begin Cardiac Monitoring Partnership - Medical Product Outsourcing
HeartBeam and AccurKardia partner on ECG tech - Investing.com
HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation - Bluefield Daily Telegraph
Heartbeam stock touches 52-week low at $1.7 amid market challenges - Investing.com Canada
Heartbeam stock touches 52-week low at $1.7 amid market challenges By Investing.com - Investing.com South Africa
Benchmark maintains $8 target on Heartbeam stock post-Q4 report By Investing.com - Investing.com Australia
Benchmark maintains $8 target on Heartbeam stock post-Q4 report - Investing.com
HeartBeam Announces Automated Cardiac Detection Patent Granted for HeartBeam AIMIGo™ System - Business Wire
HeartBeam reports net loss of USD 4.9M in Q4 2024 - Medical Buyer
HeartBeam, Inc. (NASDAQ:BEAT) Q4 2024 Earnings Call Transcript - Insider Monkey
HeartBeam’s Earnings Call Highlights Strategic Progress - TipRanks
HeartBeam (NASDAQ: BEAT) Reports Q4 and Full-Year 2024 Financial Results, Highlights FDA Clearance and Commercial Progress - The Globe and Mail
HeartBeam Inc (BEAT) Q4 2024 Earnings Call Highlights: FDA Clearance and Strategic Moves By GuruFocus - Investing.com Canada
HeartBeam Advances Cardiac Care with FDA Clearance and New Innovations - TipRanks
Earnings call transcript: HeartBEAM Q4 2024 misses EPS forecasts - Investing.com
HeartBeam Reports Fourth Quarter and Full Year 2024 Results -March 13, 2025 at 05:31 pm EDT - Marketscreener.com
Heartbeam Inc reports results for the quarter ended December 31Earnings Summary - TradingView
HeartBeam Reports Fourth Quarter and Full Year 2024 Results - Business Wire
HeartBeam (NASDAQ: BEAT) To Present At Upcoming Investor And Industry Conferences - Barchart
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025 - The Bakersfield Californian
Meet HeartBeam Executives: Key Investment Conferences Set for California Next Month - StockTitan
HeartBeam (NASDAQ: BEAT) to Present at Upcoming Investor and Industry Conferences - The Globe and Mail
HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time - The Bakersfield Californian
HeartBeam's 2024 Earnings Call: Key Updates on Cardiac Tech Commercialization Coming March 13 - Stock Titan
HeartBeam (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M - The Globe and Mail
HeartBeam closes underwriter’s over-allotment option for PO - Medical Buyer
HeartBeam Raises $11.5M: What This Capital Injection Means for Its Commercial Launch Timeline - StockTitan
HeartBeam Announces Exercise and Closing of Underwriter’s Over-Allotment Option for Public Offering of Common Stock - Business Wire
Heartbeam CFO Tim Cruickshank buys $29,999 in company stock - Investing.com India
Heartbeam director Richard Ferrari buys $50,000 in stock By Investing.com - Investing.com Australia
Heartbeam director Richard Ferrari buys $50,000 in stock - Investing.com India
Heartbeam CFO Tim Cruickshank buys $29,999 in company stock By Investing.com - Investing.com Nigeria
HeartBeam announces pricing of UPO - Medical Buyer
HeartBeam submits 510(k) application to FDA for ECG software - MSN
HeartBeam sets price for $10 million stock offering - MSN
HeartBeam prices public offering of 5.88M shares; shares down - MSN
HeartBeam Secures Major Funding: FDA-Cleared Cardiac Innovation Gets $10M Boost - StockTitan
US Penny Stocks Spotlight: HeartBeam And Two More Standout Picks - Yahoo Finance
HeartBeam (NASDAQ: BEAT) Submits FDA Application for 12-Lead ECG Synthesis Software - The Globe and Mail
Finanzdaten der Heartbeam Inc-Aktie (BEAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):